Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)
T-cell Acute Lymphoblastic Leukemia|Lymphoblastic T-Cell Lymphoma
BIOLOGICAL: CD1a-CAR T
Number of adverse events grade III-IV, Number of adverse events grade III-IV using common toxicity criteria (CTC), 1 year particularly the first 28 days after infusion|Incidence of severe Cytokine release syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS), Incidence of severe Cytokine release syndrome (CRS) (≥ grade III) and Immune effector cell-associated neurotoxicity syndrome (ICANS) (≥ grade II), 1 year particularly the first 28 days after infusion|Non-relapse treatment-related mortality (NRM), Non-relapse treatment-related mortality (NRM), 1 year|Number of adverse events of special interest (AESI), Number of adverse events of special interest (AESI), 1 year|Assessment of the immunological homeostasis, Assessment of the immunological homeostasis, through the identification of lymphocytes subpopulations by flow cytometry at each study timepoint., 1 year|Incidence of the treatment-related dermatological events, Incidence of the treatment-related dermatological events, 1 year|Number of patients developing dose limiting toxicity (DLT), Number of patients developing dose limiting toxicity (DLT), first 28 days after infusion
Remission rate, Percentage of patients presenting complete response (CR) or incomplete count recovery (CRi) at any point after treatment., 1 year|Response rates, Percentage of patients presenting CR, CRi, Complete remission duration (CRD), morphologic leukaemia-free status (MLFS), and no remission (NR)., 1 year|Duration of remission, The duration of the remission will be assessed from the first documented date of remission status until progression (in days), 1 year|Minimal residual disease (MRD) response, Minimal residual disease (MRD) response by flow cytometry: blast count among patients presenting bone marrow complete response (sensitivity 10-4)., 1 year|Progression-free survival (PFS), time since the first OC-1 administration to the documented loss of response., 1 year|Overall survival, Overall survival time since first OC-1 administration to date of death., 1 year|Persistence of OC-1, • Persistence of OC-1, as determined by flow cytometry and quantitative analysis by qPCR. Genomic copy number integrations of the CAR in peripheral blood (PB) T cells and percentage of CD1a CAR-expressing T cells., 1 year
First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)